Track market-moving stories before they get noisy

, /PRNewswire/ -- Hut 8 Corp. (Nasdaq, TSX: HUT) ("Hut 8" or the "Company"), an energy infrastructure platform integrating power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive technologies, today announced it will release financial results for the second quarter of 2026 before the market opens on August 4, 2026. The Company will host a conference call and webcast to review the results on the same day at 8:30 a.m. ET.

Conference Call and Webcast Details

Date: Tuesday, August 4, 2026
Time: 8:30 a.m. ET

To register for the webcast, use the following link: https://app.webinar.net/aA6jEPYlwy5.

Supplemental Materials and Upcoming Communications

For important news and information regarding the Company, including investor presentations and timing of future investor conferences, visit the Investor Relations section of the Company's website, hut8.com/investors, and its social media accounts, including on X and LinkedIn. The Company uses its website and social media accounts as primary channels for disclosing key information to its investors, some of which may contain material and previously non-public information.

About Hut 8

Hut 8 is an energy infrastructure platform integrating power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive technologies such as AI, high-performance computing, and ASIC compute. The Company develops, commercializes, and operates industrial-scale energy and data center infrastructure through a power-first, innovation-driven approach. For more information, visit hut8.com.

SOURCE Hut 8 Corp.

Nvidia stock's NASDAQ:NVDA latest movement has little evidence that the AI infrastructure boom is losing momentum.

NVDA jumped 4% on Friday to close at $210.96, extending their weekly gain to about 8.3% as investors returned to the AI-chip leader following a period of relative underperformance.

The advance left the stock roughly 13% higher in 2026, based on its adjusted year-end close of $186.27.

Yet a warning from Taiwan has drawn attention to the financial conditions supporting that growth.

Central bank governor Yang Chin-long told lawmakers on July 9 that AI was driving genuine economic expansion, but excessive borrowing could encourage speculative investment and overbuilding.

Taiwan matters because TSMC sits at the centre of the supply chain, serving Nvidia and other global technology companies.

Yang did not declare that AI demand was about to collapse, nor did he single out Nvidia’s valuation.

His concern was that technology companies could borrow too aggressively and expand before the financial returns from their investments were fully established.

“AI is driven by real growth potential,” Yang said at the parliamentary hearing, while warning about over-expansion caused by excessive leverage.

That distinction goes directly to Nvidia’s business model. The company supplies the processors, networking equipment and complete systems used to build AI data centres.

Large cloud operators must spend heavily on chips, buildings, electricity and cooling before those assets produce meaningful revenue.

For Nvidia, greater hyperscaler spending supports near-term sales.

But if that expenditure creates weaker cash flow, rising debt or disappointing returns, customers could eventually delay data-centre projects, keep existing hardware running for longer or increase their use of cheaper custom processors.

Taiwan has therefore highlighted a financial-cycle risk rather than a product weakness.

Nvidia could remain the dominant AI-chip supplier and still suffer if the overall infrastructure budget grows more slowly.

Bank of America remains firmly bullish. Analyst Vivek Arya reiterated a Buy rating and $350 price target, arguing that investors are undervaluing Nvidia’s pricing power.

Nvidia can “sustain” roughly 65% to 70% of AI capital spending over the long term, Arya said in a research note.

He expects the Rubin platform to command higher prices than Blackwell, helping Nvidia maintain gross margins in the mid-70% range despite rising memory costs.

Goldman Sachs analyst James Schneider has also maintained a Buy rating, with a $285 target.

Schneider noted that Nvidia traded at less than 14 times his forecast for 2027 earnings, a valuation he considers compelling given the company’s growth.

Even after allowing for market-share gains by custom AI chips and rival processors, Goldman expects Nvidia’s revenue to climb about 55% to $635 billion next year.

The message from both banks is that competition is real, but Nvidia’s valuation already reflects a considerable amount of anxiety about it.

By PYMNTS  |  July 13, 2026

 | 

Mastercard is reportedly considering a sale of its U.K. retail payments business Vocalink.

That’s according to a report Monday (July 13) from the Financial Times (FT), which says this move comes as Mastercard fields concerns about a “strategically critical” asset being under American ownership.

These discussions, the report added, come at a pivotal moment for Vocalink, which provides the systems upholding key parts of the British financial infrastructure. The company is readying itself to seek a contract to build a new payments platform for the U.K.. 

The report cites two sources briefed on the discussions, who say talks are at a very early stage. A spokesperson for Mastercard declined to comment when reached by PYMNTS.

Mastercard acquired a majority stake in Vocalink from a group of 18 British banks in 2016 for 700 million pounds. One source told the FT that a deal for a 51% stake in the company could be worth roughly 400 million pounds ($535 million).

According to the report, one potential buyer could be DeliveryCo, a new company backed by many of the U.K.’s top banks and payment firms that was established to handle the procurement and funding of the next iteration of the country’s retail payment system.

However, the sources told the FT DeliveryCo is still setting up its funding and governance arrangements, meaning a deal with Mastercard is unlikely to happen before next year.

The FT notes that the potential sale is happening amid concerns by England’s government and central bank about the lack of competition for Mastercard and Visa, which handle the wide majority of retail payments in the U.K. 

The U.K.’s Financial Conduct Authority in May announced it had launched an investigation into PayPal, Mastercard and Visa to determine whether the three companies engaged in what it called “anti-competitive conduct linked to the funding and usage of PayPal’s digital wallet.”

All three companies have said they would cooperate with the FCA’s probe.

Another source of unease is President Donald Trump’s willingness to intervene in the overseas operations of U.S. companies, the FT report added, citing the example of the White House’s recent export controls on artificial intelligence startup Anthropic.

PYMNTS Intelligence has collaborated with Mastercard on research reports, including the recent “The Cross-Border Opportunity: What Global Sourcing by US SMBs Means for Payment Providers.” It found that the wall between corporate operations and small and medium-sized business (SMB) workflows has begun to grow more porous. 

“As international sourcing becomes routine rather than exceptional, America’s small businesses are inheriting enterprise finance responsibilities ranging from foreign exchange management to supplier liquidity and cross-border cash flow,” PYMNTS wrote earlier this month.

BRENTWOOD, Tenn., July 13, 2026 (GLOBE NEWSWIRE) -- CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it is delivering an irrevocable notice to the holders of all of CoreCivic’s previously issued $250,000,000 original aggregate principal amount of 4.750% senior notes due 2027 (the “2027 Notes”) that CoreCivic has elected to redeem in full the 2027 Notes that remain outstanding on August 12, 2026 (the “Redemption Date”). The 2027 Notes were otherwise scheduled to mature on October 15, 2027. The 2027 Notes will be redeemed at a redemption price equal to 100.000% of the principal amount of the then outstanding 2027 Notes, plus the applicable “make-whole” premium specified in the indenture, as supplemented, governing the 2027 Senior Notes, plus accrued and unpaid interest to, but not including, the Redemption Date (the “Redemption Price”). As of July 13, 2026, the principal amount of the outstanding 2027 Notes was $238,468,000. CoreCivic intends to use cash on hand to fund the Redemption Price.

This press release shall not constitute a notice of redemption of the 2027 Notes.

About CoreCivic
CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. CoreCivic has been a flexible and dependable partner for government for more than 40 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements including statements regarding CoreCivic’s redemption of the 2027 Notes and its funding of the Redemption Price. These forward-looking statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Such forward-looking statements may be affected by risks and uncertainties in CoreCivic’s business and market conditions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. Important factors that could cause actual results to differ are described in the filings made from time to time by CoreCivic with the U.S. Securities and Exchange Commission (the “SEC”) and include the risk factors described in CoreCivic’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 20, 2026. Except as required by applicable law, CoreCivic undertakes no obligation to update forward-looking statements made by it to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events.

Contact:Investors: Jeb Bachmann - Managing Director, Investor Relations - (615) 263-3024 Financial Media - David Gutierrez, Dresner Corporate Services - (312) 780-7204

-

BOCA RATON, Fla.--(BUSINESS WIRE)--The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) announced today that the Company has entered into a five-year support services contract with U.S. Immigration and Customs Enforcement (“ICE”) for the activation of a federal immigration processing center at the 1,188-bed Big Horn Facility (the “Facility”) in Hudson, Colorado. GEO has entered into a lease agreement with the Facility owner.

The support services contract is expected to generate approximately $85 million in annual revenues in the first full year of operations, excluding transportation revenue. GEO’s support services are expected to include the exclusive use of the Facility by ICE, along with security, maintenance, and food services, as well as access to recreational amenities, medical care, and legal counsel.

George C. Zoley, GEO's Chairman, Chief Executive Officer and Founder, said, “We expect that our company-leased Big Horn Facility in Colorado will play an important role in helping meet the need for increased federal immigration processing center bedspace. We are proud of our 40-year public-private partnership with ICE, and we stand ready to continue to assist the federal government in meeting its immigration enforcement priorities.”

About The GEO Group

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 97 facilities totaling approximately 76,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 20,000 employees.

Use of forward-looking statements

This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the cautionary statements and risk factors contained in GEO's filings with the U.S. Securities and Exchange Commission including its Form 10-K, 10-Q and 8-K reports. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including those referenced above. GEO disclaims any obligation to update or revise any forward-looking statements, except as required by law.

More News From The GEO Group, Inc.

Back to Newsroom

This week’s Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs these companies’ health insurance businesses and their rivals are keeping a handle on rising costs. In this photo, UnitedHealthcare health insurance company signage is displayed on an office building in Phoenix, Arizona on July 19, 2023. (Photo by Patrick T. Fallon / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images)

AFP via Getty Images

This week’s Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs these companies’ health insurance businesses and that of their rivals are keeping a handle on rising costs.

Elevance, which owns Blue Cross and Blue Shield plans in 14 states, and UnitedHealth, which owns the nation’s largest health insurer in UnitedHealthcare, will be the first health insurers to report second quarter earnings as the industry works to exit a period of higher-than-expected medical costs.

These insurers’ earnings reports report will offer clues as to whether the sector may finally be turning the corner after most health plans reported medical loss ratios north of 90% until the trend was interrupted with lower costs in the first quarter of this year. Such a ratio, which is the percentage of premium revenue that goes toward medical costs, was above 90% for much of 2025 for many insurers.

In the first quarter of this year, however, Elevance, which is the nation’s second-largest health insurer behind UnitedHealthcare, reported a benefit expense ratio eclipsing 86%. Elevance manages Medicaid coverage for poor Americans via contracts with multiple states, sells Medicare Advantage for older adults and markets commercial health insurance including individual coverage under the Affordable Care Act, also known as Obamacare. The company also has a growing Carelon healthcare services business.

“The benefit expense ratio was 86.8 percent, an increase of 40 basis points, reflecting expected elevated medical cost trend in our Medicaid business, partially offset by improved performance in Medicare,” Elevance Health said in its first quarter earnings statement.

MORE FOR YOU

Analysts who follow the industry say they expect second quarter earnings reports to show that companies have maintained their handle on medical cost trends, particularly in their Medicare Advantage plans. Medicare Advantage plans contract with the federal government to provide coverage available in traditional Medicare plus extra benefits and services to seniors, such as disease management and nurse help hotlines with some also offering vision, dental care and wellness programs.

UnitedHealth said in its first quarter report that its “medical cost ratio was 83.9% for the first quarter 2026, down 90 basis points from the first quarter 2025.”

Elevance reports Wednesday, July 15 and UnitedHealth reports Thursday, July 16.

Hledat v komentářích

Investiční doporučení

Výsledky společností - ČR

Výsledky společností - Svět

IPO, M&A

Týdenní přehledy

Detail - články

13.07.2026 11:41

ČEZ, a. s.
(IČ 45274649)

Společnost ČEZ, a.s. zveřejňuje vnitřní informaci Elevion Group podepsal kupní smlouvu na akvizici 100% podílu v italské společnosti BTS Biogas, posílí tak v sektoru bioplynových a biometanových stanic. Více informací zde.

(komerční sdělení)

Tagy: Povinně uveřejňované informace
Reklama

Na tomto místě můžete zahájit diskusi. Zatím nebyl zadán žádný názor. Do diskuse mohou přispívat pouze přihlášení uživatelé (Přihlásit). Pokud nemáte účet, na který byste se mohli přihlásit, registrujte se zde.

Aktuální komentáře

13.07.2026 11:41ČEZ, a.s.: Vnitřní informace - Elevion Group podepsal kupní smlouvu na akvizici 100% podílu v italské společnosti BTS Biogas 10:58TSMC má za druhé čtvrtletí rekordní tržby 10:07Nejhorší den na burze. Akcie SK Hynix potkal více než 15procentní výplach 8:52Eskalace konfliktu s Íránem zhoršuje náladu na trzích. SK Hynix po americkém debutu propadl   8:47Rozbřesk: Hormuz znovu straší trhy. Česká ekonomika však drží kurz 6:03Wood: Úvahy o konci americké výjimečnosti jsou notně přehnané 12.07.2026 9:22Víkendář: Greenspan předpovídal inflaci 4,5 % a 8% výnosy z desetiletých amerických státních dluhopisů 11.07.2026 9:21Víkendář: Greenspan se evidentně mýlil, akcie nebyly v roce 1996 nijak nadhodnocené 10.07.2026 17:39Nemělo by se nyní více mluvit o nesprávném monetárním kurzu? 16:08Bylo by nebezpečné vědět, proč centrální banky jednají tak, jak jednají? 14:10Analytici otáčejí. Očekávání zisků evropských firem rostou nejrychleji za dva roky   12:22Perly týdne: Červená karta pro Američany a klesající dynamika akcií malých firem 11:02Volkswagen spouští jednu z největších proměn ve své historii. Omezí výrobu i nabídku modelů 10:51Techy korigují včerejšek, ale trhy mezitím podporuje obnovení jednání s Íránem   10:41ExxonMobil může těžit z návratu geopolitických rizik. Má prostor pro růst akcií   9:24O easyJet se rozhořel boj. Apollo nabídlo víc než konkurence a získalo podporu vedení 9:01Rozbřesk: Polská centrální banka drží sazby, Glapiński se nebrání podzimnímu snížení 8:54Babiš otevřel debatu o IPO Letiště Praha, ČNB varuje před návratem inflace a optimismus kolem AI se vrací   6:04Nejvýnosnější akciový trh roku? Jižní Koreu sesadila Nigérie 09.07.2026 17:25Pracují nyní trhy pro Fed nebo proti němu? A jak dopadnou testy nových monetární myšlenek?
Reklama

Související komentáře

Nejčtenější zprávy dne

Nejčtenější zprávy týdne

Nejdiskutovanější zprávy týdne

Kalendář událostí

Nebyla nalezena žádná data

Potřebujte poradit?

Shares of Nike (NKE +3.72%) closed Friday at about $44, up nearly 4% and extending a rebound that began when the company reported fiscal fourth-quarter results at the end of June. Even after that bounce, the stock sits about 44% below its 52-week high of $80.17.

Adding to the intrigue is CEO Elliott Hill, who has been putting his own money into the stock near its lows. This begs the question: Is this a good time to follow the CEO into the stock?

Image source: The Motley Fool.

A profit built mostly on a refund Nike's fiscal fourth quarter of 2026 (the period ended May 31, 2026) looked, at a glance, like a breakout. Revenue came in at $11.0 billion, and net income jumped 407% year over year to $1.1 billion. Diluted earnings per share reached $0.72.

But most of that bottom-line surge traces to a single item. Of the $0.72 in earnings per share, $0.52 came from an expected recovery of import duties Nike had paid under the International Emergency Economic Powers Act (IEEPA) -- a nearly $1 billion accounting benefit booked after courts struck down the tariffs. Strip it out, and the company earned about $0.20 per share from running its business.

The same distortion shows up in margins. Nike's gross margin jumped about 9 percentage points, to 49.2%. But almost all of that came from the tariff recovery. Strip it out, and the underlying gross margin was roughly flat -- near 40%, about where it sat a year earlier.

Fourth-quarter revenue fell 1% year over year, and dropped 4% on a currency-neutral basis, which strips out the effect of a weaker dollar. That currency-neutral decline widened as the year went on, from about 1% in the fiscal first quarter to 4% in the fourth. For the full year, sales were essentially flat -- a stabilization after the prior year's steep drop, not yet a recovery. So the reported steadiness owed something to currency, and the profit jump owed almost everything to a one-time refund.

North America is the part that's turning Underneath the noise, though, one figure suggests the turnaround is more than a story management is telling. Revenue in North America, Nike's largest market, rose 3% year over year to $4.83 billion in the quarter, and climbed 5% for the full fiscal year. After a long slide, Nike's home market is finally growing again, led by a rebound in its wholesale channel as the company rebuilds relationships with the retail partners it had spent years walking away from.

Meanwhile, Greater China, once one of Nike's most dependable growth drivers, fell another 12% in the quarter and 11% for the full year. And Nike Direct, the company's own stores and app, kept sliding, as management deliberately routes more sales back through wholesale partners.

In other words, North America is inflecting, but it hasn't yet pulled the whole company back to growth.

Then there's the insider buying. CEO Elliott Hill has twice put about $1 million of his own money into Nike shares on the open market -- once in late December, near $61 a share, and again in April, near $42, close to the stock's low. Other insiders bought around the same time, including board member Tim Cook -- the CEO of Apple.

Of course, insider purchases guarantee nothing about the stock's prospects. Even inside executives can misjudge their own companies. But a chief executive buying more as the price falls at least signals that the people closest to the business think it's worth more than the market does. So, it's at least worth some consideration.

Today's Change

(

3.72

%) $

1.59

Current Price

$

44.37

But what about the stock's valuation?

At about $44, Nike trades at about 21 times earnings. But that multiple is inflated by the one-time tariff benefit baked into the past year's profit. Strip it out, and the price-to-earnings ratio is closer to 28 -- hardly a bargain for a business whose sales are still shrinking outside North America.

So, is the stock a buy here? I'm encouraged, but I'm not buying yet. The recovery in North America and Hill's willingness to buy near the lows are the most convincing signs of a turnaround Nike has offered investors in a while. But the headline profit leans on an accounting item that won't return, and the parts of the business that most need to inflect -- Greater China and the direct-to-consumer channel -- still haven't. At this valuation, I'd want to see companywide sales turn positive on a currency-neutral basis and China stop falling before treating the turnaround as more than early. Until then, I'm content to watch a genuinely improved story get a quarter or two closer to proving itself.

- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD)

- Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study

- Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris.

“These results continue to build a highly consistent body of evidence supporting latarcibart as a significant potential treatment advancement for patients with VWD,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of R&D.

Share Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Given its novel mechanism, latarcibart may also have potential in other bleeding disorders.

“These results continue to build a highly consistent body of evidence supporting latarcibart as a significant potential treatment advancement for patients with VWD,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “This multidose dataset underscores the potential of latarcibart to address the longstanding need for a prophylactic therapy that provides meaningful protection for patients with all types of VWD. We are continuing to enroll the Phase 3 VIVID-6 study as we work toward redefining the standard of routine prophylactic care for patients with VWD.”

As of May 5, 2026, data from all 16 patients enrolled in the Phase 1/2 multidose study were available, and all participants had completed the multidose regimen of six doses of latarcibart, with maintenance doses administered subcutaneously every four weeks. Key data highlights include:

Substantial reductions in ABR (annualized bleeding rate) were seen across study patients, including all VWD types and bleed types, such as serious GI and hemophilia-like joint and muscle bleeds. The median ABR reduction across all VWD types and bleed categories was 81%. In patients switching from prior von Willebrand factor (VWF)-containing prophylaxis (IV infusions multiple times per week), bleed reductions were 75-100%, indicating potential improvement over current standard of care. Among patients not previously receiving IV prophylaxis, 7 had historical ABRs >12, a key eligibility criterion for the Phase 3 VIVID-6 study. In this group, ABR reductions ranged from 46-100%, with nearly all patients (6/7) achieving reductions >73%. Latarcibart treatment resulted in ~86% reduction in VWF-treated breakthrough bleeds, with 70% of patients with prior VWF-treated bleeds not experiencing a VWF-treated breakthrough bleed while on treatment. All participants who entered the study with a substantial bleed burden transitioned to continue receiving latarcibart in the ongoing open-label extension study. Latarcibart once monthly subcutaneous prophylaxis was safe and well tolerated over multiple doses. Three treatment-emergent adverse events (TEAEs) related to latarcibart were reported: two Grade 2 headaches in one patient and one report of Grade 1 injection site reactions. There was also one unrelated serious adverse event of severe gastrointestinal (GI) bleeding in a patient with a history of frequent and severe GI bleeding. “Many people with VWD struggle with bleeding and need more effective and convenient prophylactic treatments. The study results showed treatment with latarcibart delivered consistent and clinically meaningful reductions in bleeding across a diverse group of VWD patients, including patients with all major types of the disease and individuals transitioning from intensive IV prophylaxis,” said Allison Wheeler, M.D., MSCI, Associate Professor of Pediatrics at the University of Washington. “Equally important, the favorable safety profile and once monthly subcutaneous dosing regimen have the potential to substantially reduce treatment burden while providing consistent bleed protection. Together, these findings provide a strong foundation for the Phase 3 study and support latarcibart’s potential as an important new treatment option for patients with VWD.”

More information regarding the ISTH 2026 Congress can be found on the ISTH website: https://www.isthcongress.org/ (Session details: Novel Therapies for Bleeding Disorders, Including VWD and Rare Bleeding Disorders – 2; Publication Number: OC 32.3).

About VGA039 (latarcibart)

VGA039 (latarcibart) is an investigational monoclonal antibody therapy with a novel mechanism of action that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. Latarcibart has the potential to be a universal prophylactic therapy for numerous bleeding disorders, starting with all types of von Willebrand disease (VWD) and bleeding sites. As a subcutaneously self-administered investigational antibody therapy with a once monthly dosing regimen, latarcibart has the potential to improve bleeding outcomes, convenience, and quality of life for patients.

Latarcibart has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration (FDA). Latarcibart has advanced into the Phase 3 VIVID-6 study (NCT07115004), a global single arm cross-over study to investigate safety and efficacy of the subcutaneous administration of latarcibart as prophylaxis for bleeding in patients with every type of VWD, including those with a high disease burden.

Incyte acquired VGA039 (latarcibart) in July 2026 as part of its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC.

About the VIVID Clinical Program

The VIVID multinational clinical program consists of multiple clinical trials, from Phase 1 to 3, in both a platform multi-phase protocol (VIVID-1-5) and a standalone Phase 3 protocol (VIVID-6) evaluating the safety and efficacy of VGA039 in VWD. The VIVID clinical program is active across 6 continents and designed to support future registrational filings globally.

About von Willebrand Disease

Von Willebrand disease (VWD) is the most common inherited bleeding disorder in which the blood does not clot properly, caused by low or defective von Willebrand factor (VWF). People with VWD may experience excessive bleeding with varying severity and frequency, negatively impacting their daily lives. Current therapies for VWD prophylaxis include factor replacement therapies requiring multiple intravenous (IV) infusions every week. Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.1

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the data to be presented by Incyte at the ISTH 2026 Congress; Incyte’s expectations regarding VGA039’s (latarcibart’s) clinical development and regulatory approvals; the potential and promise latarcibart offers patients with bleeding disorders, including the potential to be the first once monthly subcutaneous prophylactic therapy for patients with VWD, its potential improvement over current standards of care for patients with VWD and other bleeding disorders, and its potential ability to address significant unmet need, reduce treatment burden and improve quality of life; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including results from clinical trials of and the sufficiency of clinical trial data for latarcibart, as well as Incyte’s other products and product candidates, to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Incyte’s ability to achieve commercial success for latarcibart, if approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.

Intuitive Surgical, Inc. (NASDAQ:ISRG) will release its second quarter earnings report after the closing bell on Thursday, July 16.

Analysts expect the Sunnyvale, California-based company to report quarterly earnings of $2.50 per share, up from $2.19 per share in the year-ago period. The consensus estimate for Intuitive Surgical’s quarterly revenue is $2.82 billion. It reported $2.44 billion last year, according to Benzinga Pro.

On May 28, Intuitive announced the promotion of global senior vice president of Intuitive’s endoluminal business Taylor Patton to chief commercial and marketing officer.

Intuitive Surgical shares fell 1.2% to close at $406.78 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying ISRG stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Taiwan Semiconductor Manufacturing Co. reported a 67.9% year-on-year rise in its June sales on Monday, ahead of its second-quarter earnings release later this week.

For the first half of 2026, TSMC's total revenue reached 2.4 trillion new Taiwan dollars ($74.99 billion), representing a 35.6% increase compared to the same period in 2025. TSMC reported June revenue of NT$ 442.68 billion — a 6.2% increase from the previous month.

The Taiwanese chip giant's shares were trading 1% higher Monday.

The company' growth has been boosted by demand for artificial intelligence chips and infrastructure investments. 

The world's largest contract chipmaker manufactures semiconductors for a wide range of applications, spanning from smartphones to high-performance AI computing systems, with key clients including U.S. technology leaders such as AI darling Nvidia, Apple and Advanced Micro Devices.

TSMC plans to add two advanced chip packaging plants in the Chiayi Science Park in southern Taiwan, Reuters reported, citing remarks made by Taiwan's National Science and Technology Council Minister Wu Cheng-wen on Sunday. Wu noted that the site's first facility is already in mass production, with the second expected to begin shortly. 

TSMC, which commands a 73% share of the global pure-foundry market — chips manufactured for clients — in the first quarter of 2026, according to data from Counterpoint Research, is set to report its second-quarter earnings on Thursday, July 16. 

A general view of the Taiwan Semiconductor Manufacturing Company's (TSMC) fabrication plant in Kaohsiung, Taiwan, June 7, 2025. REUTERS/Ann Wang Purchase Licensing Rights, opens new tab

TAIPEI, July 13 (Reuters) - Taiwan Semiconductor Manufacturing Co (TSMC) (2330.TW), opens new tab will add two advanced chip ​packaging plants in the Chiayi Science Park, ‌the island's science and technology minister said on Sunday.

Located in southern Taiwan, the Chiayi Science ​Park is being developed as one ​of TSMC's major advanced chip-packaging hubs.

Make sense of global markets with the Trading Day newsletter. Sign up here.

TSMC's ⁠first advanced chip packaging plant at the ​Chiayi Science Park has already entered mass ​production and its second plant is expected to begin mass production soon, National Science and Technology ​Council Minister Wu Cheng-wen said at a ​groundbreaking ceremony.

"Today's groundbreaking marks the start of the second ‌phase, ⁠which will include a third and fourth plant," Wu said, adding that the park is expected to generate more than ​300 billion ​Taiwan dollars ($9.35 ⁠billion) in annual production value and create more than 9,000 ​jobs once all four plants are ​up ⁠and running.

TSMC is rapidly expanding its advanced chip-packaging capacity, including its chip-on-wafer-on-substrate technology, as ⁠demand ​from artificial intelligence chip ​designers like Nvidia (NVDA.O), opens new tab continues to outstrip supply.

($1 = 32.0970 Taiwan dollars)

Reporting ​by Wen-Yee Lee; Editing by Thomas Derpinghaus

Our Standards: The Thomson Reuters Trust Principles., opens new tab

After hitting a 52-week high of $1,255 on June 25, the Micron Technology (MU 1.05%) stock price has since retreated below $1,000. There's a likely mix of factors that have led to that decline and that are keeping the stock price from rebounding, ranging from potential profit-taking to a chip stock sell-off to increased competition from SK Hynix's listing on the Nasdaq.

In the background, however, there was a July 6 announcement from Micron that seemed to get buried.

Image source: The Motley Fool.

Micron locks in Ford On July 6, Micron Technology announced that it had entered into a long-term agreement, which it called a strategic customer agreement (SCA), with Ford to help strengthen the automaker's vehicle production. "Producing the high-volume vehicles of the future in the U.S. will require a resilient supply chain," Ford CEO Jim Farley said in the announcement.

Micron didn't offer specifics about the deal's value. But it did say the SCA was part of a collective 16 it discussed in its 2026 third-quarter earnings call.

Today's Change

(

-1.05

%) $

-10.39

Current Price

$

981.25

In that call, Micron shared that it had strategic agreements, ranging from deals with automakers to hyperscalers, spanning three to five years. From those 16 agreements, it has $22 billion in deposits and financial commitments. In total, those agreements are expected to generate over $100 billion in revenue, a figure that may be conservative.

The news alone didn't push Micron back to its 52-week high of $1,255. But working to lock in future revenue over the years ahead can help it shed its cyclical reputation, building a stronger case for Micron as a long-term investment.

Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Micron Technology. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Panchenko Vladimir / Shutterstock.com

The VanEck BDC Income ETF (NYSEARCA:BIZD) just delivered a jolt to income investors: its July distribution came in at $0.24 per share, roughly half the $0.48 paid in April. BIZD passes through the dividends of the business development companies it owns, so when the underlying BDCs strain, BIZD’s payout wobbles. With the fund down 14% over the past year and BDCs facing base-rate cuts and spread compression, the question is whether this distribution is a one-off dip or the start of something worse.

How BIZD Actually Pays You BIZD tracks the MVIS US Business Development Companies Index, holding a concentrated basket of publicly traded BDCs that lend to middle-market firms at floating rates over SOFR. When those loans pay interest, the BDCs distribute nearly all of it to shareholders to preserve their tax status, and BIZD passes that income through quarterly. Roughly 90% or more of BDC loan books are floating rate, which is why the Fed’s 75 basis point cut since September 2025, taking the target to 3.75%, hits BIZD’s income at the source.

The Four Holdings That Decide BIZD’s Fate Ares Capital (NASDAQ:ARCC | ARCC Price Prediction), the largest BDC by market cap at $13.48 billion, held its quarterly dividend at $0.48 for the eighth straight quarter. Q1 core EPS of $0.47 fell a penny short, but net investment income of $0.55 per share gives real cushion. Non-accruals ticked up to 2.1% from 1.8%, worth watching, but a $1.8 billion investment backlog and $6 billion in liquidity support the payout.

Blue Owl Capital (NYSE:OBDC) already made the cut official. On May 5, 2026, the board dropped the base dividend from $0.37 to $0.31, a 16% reduction in annualized payout. CEO Craig Packer cited “a more challenging earnings environment driven by lower base rates and tighter spreads.” Adjusted EPS of $0.31 now exactly matches the new dividend, meaning zero buffer. Shares are down 15% over the past year.

Blackstone Secured Lending (NYSE:BXSL) looks like the next domino. NII of $0.77 covered the $0.77 dividend at exactly 100%, down from 104% in Q4. New investments are being originated at 7.7% while assets rolling off yielded 9.1%, which mechanically compresses future income. Non-accruals jumped to 3.1% of fair value from 0.6% a quarter earlier. CEO Brad Marshall’s own words: “non-accruals increased during the quarter from historically low levels.” Another miss, and BXSL follows OBDC.

Main Street Capital (NYSE:MAIN) is the fund’s insurance policy. Distributable NII of $1.00 per share comfortably covers the $0.26 monthly regular plus a $0.30 quarterly supplemental, now paid for 19 consecutive quarters. NAV per share rose to about $33. MAIN’s lower-middle-market focus and equity co-investments generate returns other BDCs can’t match. Retail readers who like this profile may also want our 7 Monthly Dividend Stocks report.

Total Return Reality Check BIZD’s trailing 12-month distributions of $1.52 look generous against a roughly $13 share price, but the fund is down 6% year-to-date on top of last year’s decline. The forward annualized rate has reset to $0.96, so shoppers pricing this off the trailing yield are anchored to a payout that has already stepped down.

The Verdict BIZD’s distribution is at risk of further reduction. OBDC is done cutting for now, but BXSL is running on fumes at 100% coverage with rising non-accruals, and ARCC’s cushion is thinner than a year ago. MAIN is the anchor doing the heavy lifting. For investors who need a predictable check, MAIN offers more coverage than the blended pass-through. BIZD still makes sense for someone who wants diversified BDC exposure and can tolerate a variable payout that reflects whatever the underlying managers can actually earn each quarter.

Contact [email protected] for any questions or corrections.

, /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.

According to the collaboration agreement, the two parties will jointly advance the co-development of the R&D program by combining Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&D team and deep therapeutic expertise. Insilico Medicine is eligible to receive up to approximately 1.2 billion RMB in milestone payments plus royalties. This partnership marks a deepening collaboration that leverages both parties' complementary strengths across the full value chain—from drug discovery and clinical development to commercialization.

Mr. Lam Kong, the Chairman, Chief Executive Officer, President and Executive Director of CMS said: "CMS is deeply impressed by Insilico Medicine's capability and productivity in AI drug discovery. We are happy to deepen our collaboration with Insilico Medicine. Insilico Medicine's leadership in AI drug discovery platforms and data-driven R&D is strategically complementary to CMS's capabilities in innovative R&D and clinical translation. In addition, CMS has built solid strengths in clinical development systems and efficiency, regulatory submission expertise, and commercialization network coverage. Our goal never changes: to accelerate the delivery of more clinically meaningful innovations to patients with greater speed and quality, better meeting the growing clinical needs."

"We are delighted to establish another collaboration with China Medical System just three months after our initial announcement," said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. "Our existing partnership, announced earlier this year, has been seamless and productive since its inception. In this new program, we value the input from the CMS commercialization team and are proud of the innovative Mechanism of Action (MoA) identified by PandaOmics, which streamlines the development of high-potential drugs, enhancing translational efficiency, and accelerating the transition of molecules from 'proof of concept' to life-changing patient therapies. We will continue to deepen our multi-dimensional collaboration in pipeline and clinical strategy and global partnerships to provide patients with more differentiated and accessible treatment options."

About CMS

CMS (HKEX stock code:867; SGX stock code: 8A8) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/gastroenterology/ophthalmology/ skin health businesses, bringing economies of scale in specialty fields.

About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com

SOURCE Insilico Medicine

Manuel Alba, a Director at Astera Labs, Inc. (ALAB 1.07%), executed a sale of 8,491 shares of common stock on July 1, 2026, according to an SEC Form 4 filing.

Transaction summaryMetricValueTransaction value$3.9 millionShares sold (indirectly held)8,491Post-transaction shares (directly held)2,351Post-transaction shares (indirectly held)291,863Transaction value based on SEC Form 4 weighted average sale price ($458.38); post-transaction value based on July 1, 2026 market close ($430.86).

Key questionsWhat was the mechanism for this transaction?
The sale was executed automatically under a Rule 10b5-1 trading plan that Manuel Alba adopted on May 29, 2025, which allows insiders to schedule trades in advance to avoid concerns regarding material non-public information.How are the remaining shares held?
The vast majority of the reported equity is held indirectly, with 286,863 shares owned by Casa Alameda 2007, LLC, where the Director serves as manager, and 5,000 shares held by a spouse.What is the recent performance context for the company?
As of July 2, 2026, shares were priced at $406.42, following a period of appreciation where the stock delivered a 386% total return in the year leading up to the transaction date.What is the company's current financial profile?
Headquartered in Santa Clara, the company operates in the semiconductor industry with a market capitalization of $70 billion and reported trailing twelve-month revenue of $1.0 billion as of July 7, 2026.Company OverviewMetricValueShare Price (as of market close 2026-07-02)$406.42Market Capitalization$69.7 billionRevenue (TTM)$1.0 billionNet Income (TTM)$267.6 millionCompany SnapshotAstera Labs develops and markets semiconductor-based connectivity solutions through its Intelligent Connectivity Platform, which comprises data, network, and memory connectivity products designed to serve cloud computing and artificial intelligence infrastructure markets.The company generates revenue through a software-defined architecture approach that enables customers to deploy and operate high-performance cloud and AI systems at scale, leveraging proprietary semiconductor technology and integrated software solutions.The company primarily serves hyperscale cloud service providers and enterprise customers requiring advanced connectivity infrastructure for AI and cloud computing applications.Astera Labs is a semiconductor connectivity specialist founded in 2017 that has achieved significant scale with $1.0 billion in TTM revenue and a market capitalization of $69.7 billion. The company's Intelligent Connectivity Platform addresses critical infrastructure bottlenecks in cloud and AI deployments, positioning it at the intersection of two of the highest-growth technology markets. With a lean operational footprint of 440 employees and TTM net income of $267.6 million, Astera Labs demonstrates strong operational leverage and profitability in a capital-intensive industry.

What this transaction means for investorsThis sale ultimately seems like a director trimming a rounding error off a very large win, and the proportions make that clear. Alba let go of 8,491 shares under a plan he set more than a year ago, but he still controls roughly 292,000 shares, almost all of it held through an LLC he manages. Given that the director parted with under 3% of his position on a preset schedule, selling at $458 after this kind of run is nothing to read too deeply into.

That’s also partly because the business is firing on every cylinder. Astera's first-quarter revenue hit a record $308.4 million, up 93% from a year earlier, with PCIe 6 products now more than a third of the mix and non-GAAP operating margin near 36%. CEO Jitendra Mohan tied the growth to demand for the company's connectivity platform and its new Scorpio switches ramping into the second half. Of course, it’s important to watch valuation after this kind of run-up. At a $70 billion market cap after a year in which shares have basically quadrupled, this stock is priced for years of what investors might expect to be flawless execution, so any dwindling expectations could lead to a strong reset in the stock’s price.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Astera Labs. The Motley Fool has a disclosure policy.

Amazon (AMZN 0.69%) is reported to have made a shocking decision in recent days. According to CNBC, it is issuing $25 billion in debt to fund its data center build-out. While it doesn't plan to issue any more debt beyond that in 2026, it's a big deal because Amazon's long-term debt has been soaring in the past few years.

Building data centers isn't cheap, and the cash has to come from somewhere, but is this the right move, or should it scare investors?

Image source: Getty Images.

The payoff could be immense In recent years, Amazon's debt load has skyrocketed from the company's historical levels.

AMZN Total Long Term Debt (Quarterly), data by YCharts.

The latest $25 billion sale of debt adds to this total, but Amazon has the cash flow to fund the repayment. The reality is that it's vital for the company to grab as much cloud infrastructure market share as possible in these early days of the AI build-out; it will be more difficult to win clients away from other cloud providers once everyone has their preferred vendor.

The company is currently leading the way among AI hyperscalers in data center construction plans, and it expects to lay out around $200 billion in capital expenditures this year. Over the past 12 months, Amazon generated just shy of $150 billion in cash from operations, so the gap between funds coming in and cash flowing out had to be closed somehow.

AMZN Cash from Operations (TTM), data by YCharts; TTM = trailing 12 months.

As a result, investors should not feel too blindsided by this debt issuance. But is it worth it?

CEO Andy Jassy said in his shareholder letter that the nature of a cloud computing business requires increased capital input when it's growing rapidly. Data centers aren't cheap to bring online, but they do have great payoffs over long time frames. Jassy also mentioned that a significant amount of the new computing capacity that $200 billion will buy is already under contract to customers, so it isn't just taking a leap of faith when building these data centers.

Once the construction is over and the company is benefiting from a much larger cloud computing footprint, its gains in revenue and cash flow will be immense, and should dwarf any concerns about its rising debt load. Current market conditions and demands dictate that management build more data centers, and that's exactly what it's doing.

With Amazon Web Services being a major part of the cloud computing landscape and an important part of the company's overall business, now is a perfect time to buy the stock, as Amazon's growth over the next few years could be immense.

3 Stocks Cashing In on AI While Everyone Watches NVIDIAMasTec NYSE: MTZ said it has entered into a definitive agreement to acquire The Superior Group, an electrical infrastructure contractor focused on data centers and other mission-critical markets, in a transaction valued at approximately $1.65 billion upfront.

Chief Executive Officer Jose Mas said on the conference call that the acquisition expands MasTec’s position in infrastructure tied to artificial intelligence, cloud computing and digital infrastructure. He described Superior as “one of the premier electrical infrastructure contractors” serving hyperscalers, data center developers and mission-critical customers across the United States.

Get MasTec alerts:

3 Energy Stocks to Buy as AI Power Demand Surges—and 2 to Avoid“We believe this represents a generational infrastructure investment opportunity for the companies with the capabilities, skilled workforce, and track record to help build it,” Mas said.

Deal Terms and Financing Chief Financial Officer Paul DiMarco said the purchase price consists of $1.175 billion in cash and $475 million in MasTec common stock, along with a performance-based earn-out tied to Superior’s financial results over the three years after closing. MasTec expects to issue approximately 1.2 million shares as part of the equity consideration.

This infrastructure construction stock: Is it ready to pop?DiMarco said MasTec expects to fund the cash portion through cash on hand, borrowings under its existing credit facility and delayed-draw term loan facilities arranged for the transaction. The company expects the deal to close later this month after regulatory clearance.

The upfront consideration represents 6.9 times Superior’s expected 2026 EBITDA, DiMarco said. In response to an analyst question, Mas said MasTec expects the earn-out to add about one additional turn to the upfront multiple, depending on Superior’s performance. He added that the earn-out is uncapped and based on performance targets over three years.

Expected Financial Contribution MasTec said it expects the acquisition to be immediately accretive to revenue, adjusted EBITDA, earnings per share and cash flow from operations.

For 2026, MasTec expects Superior to contribute approximately five months of earnings to consolidated results, including:

$800 million to $900 million of revenue; $100 million to $150 million of adjusted EBITDA; and $0.50 to $0.65 of adjusted earnings per share. For the full year 2026, Superior is projected to generate approximately $1.6 billion to $1.7 billion of revenue and $225 million to $250 million of adjusted EBITDA. Looking ahead to 2027, MasTec expects Superior to generate $2.2 billion to $2.5 billion of revenue and $250 million to $275 million of adjusted EBITDA.

DiMarco said the expectations are preliminary, reflect a conservative approach and do not include revenue synergies, cross-selling opportunities or operational benefits from combining the businesses. Superior will become a new operating group within MasTec, and its results are expected to be reflected in the Power Delivery segment.

Data Center and Power Infrastructure Focus Mas said the transaction strengthens MasTec’s position in markets where power infrastructure, communications infrastructure and data center development are converging. He said MasTec already delivers critical infrastructure that brings power, communications and energy to data center campuses, while Superior adds capabilities “inside the campus” through electrical construction, integrated systems, prefabrication, commissioning support and maintenance services.

Mas said the combination gives MasTec a broader offering across the infrastructure value chain. He said customers increasingly want larger, integrated partners that can self-perform work, mobilize labor at scale and deliver complex projects with speed and reliability.

In response to a question from Citigroup analyst Andy Kaplowitz, Mas said MasTec has historically performed much of the work outside the building, while Superior performs work inside the building. He said the combination could allow MasTec to offer a more turnkey service to customers, including general contractors.

Superior’s Workforce and Growth Profile Superior has approximately 3,000 employees. Mas said access to skilled labor is one of the most important competitive advantages in the industry and described Superior’s workforce as one of the company’s most attractive assets.

During the Q&A, Mas said Superior is currently an all-union business and characterized the transaction as “a bet on labor scarcity.” He said Superior’s workforce has grown almost 400% over the last few years and that the company has shown a strong ability to recruit, train and deploy skilled electrical labor.

Mas also said Superior has grown 100% organically, with no history of acquisitions contributing to its recent expansion. He said the business has operated primarily in three states in recent years, but has signed contracts that will expand it into five states next year, with the potential for additional state expansion after that.

Asked about Superior’s backlog, Mas said MasTec conducted project-by-project due diligence and has “enormous conviction” in its 2027 expectations. He said Superior has five large customers and a blue-chip customer base, adding that MasTec expects backlog to grow significantly through the balance of the year.

Balance Sheet Outlook DiMarco said MasTec expects pro forma net leverage to be modestly above two times at closing, but expects net leverage to decline below two times by the end of 2026 due to the combined company’s expected earnings and cash flow generation.

He said the transaction should generate a low double-digit return on invested capital in the first year and support MasTec’s stated target of 16% in 2028. DiMarco also said MasTec remains committed to maintaining strong liquidity and preserving its investment-grade credit profile.

Mas said the company sees the data center build-out as still being in its early stages, based on conversations with customers, hyperscalers and advisors during due diligence. He acknowledged that the market may see “ups and downs,” but said MasTec remains bullish on the long-term opportunity.

About MasTec NYSE: MTZMasTec, Inc is a diversified infrastructure construction company that provides engineering, fabrication, installation and maintenance services across a broad range of end markets. Its principal activities encompass the development of communications networks, oil and gas pipeline systems, electrical transmission and distribution facilities, industrial installations and renewable energy projects.

The company traces its roots to a small cable installation operation in Miami and has grown through a series of strategic acquisitions to become one of the largest infrastructure contractors in North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in MasTec Right Now?Before you consider MasTec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MasTec wasn't on the list.

While MasTec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Meta Platforms (META +6.16%) just closed out quite an eventful week. Shares of the social media giant jumped about 6% on Friday alone as investors warm back up to CEO Mark Zuckerberg's aggressive artificial intelligence (AI) strategy.

The company has given them plenty to work with this year. Growth is accelerating, its new AI lab released its first model this spring, and capital spending guidance now tops $125 billion.

But let's zoom out for a second. How has the stock done over the long haul? Specifically, how much would $10,000 invested in Meta a decade ago be worth today?

Image source: Getty Images.

How the math works out In 2016, Meta -- then still called Facebook -- traded at an average price of about $116 per share. A $10,000 investment at that price would have bought about 86 shares. With the stock trading near $670 as of this writing, those shares would be worth roughly $57,600 today, a nearly sixfold gain.

And dividends sweeten the total a little. Meta initiated its first-ever dividend in early 2024 at $0.50 per share quarterly, and the quarterly payout now stands at $0.525 per share. Those 86 shares would have collected a bit over $400 in dividends so far, bringing the total value to about $58,000.

That works out to a compound annual growth rate of about 19%.

The engine hasn't slowed Of course, none of that return is available to anyone buying today. What matters now is whether the business that produced it is still performing.

What impresses me most is that ten years in, Meta's growth is accelerating, not fading. Revenue rose 22% in 2025 to $201.0 billion, and the growth rate stepped up through the year, from 24% year over year in the fourth quarter to 33% in the first quarter of 2026, when revenue hit $56.3 billion. The formula hasn't changed, either. The company sells more ads, at higher prices, across Facebook, Instagram, WhatsApp, and Messenger. Ad impressions rose 19% year over year in the first quarter, the average price per ad rose 12%, and an average of 3.56 billion people used at least one of Meta's apps each day in March.

All that advertising produces enormous profits. Meta's first-quarter operating income rose 30% year over year to $22.9 billion. And shareholders are seeing plenty of the cash. The company spent over $26 billion on share repurchases in 2025, paid another approximately $5 billion in dividends and dividend equivalents, and still ended the year with more than $81 billion in cash and marketable securities.

And the company is spending like it believes the next decade holds more. Meta recently raised its 2026 guidance for capital expenditures to a range of $125 billion to $145 billion, much of it aimed at AI infrastructure. Its second-quarter outlook, meanwhile, calls for revenue of $58 billion to $61 billion.

"We had a milestone quarter with strong momentum across our apps and the release of our first model from Meta Superintelligence Labs," said Zuckerberg in the company's first-quarter earnings release.

That spending is also the market's biggest worry about the stock. If the AI investments don't pay off in continued growth, today's expense ramp could weigh on profits for years to come. This past week, at least, investors treated the spending as a positive.

Today's Change

(

6.16

%) $

38.92

Current Price

$

670.40

Should investors expect a repeat? Sure, the backtest is fun. But nobody should buy Meta stock expecting another 19% a year for a decade. The company is vastly larger today than it was in 2016, and growth can get harder with size. Additionally, competition for attention and ad dollars isn't easing, and regulators around the world continue to scrutinize the company.

But the stock's price doesn't demand a repeat, either. Shares trade at about 19 times forward earnings -- a reasonable multiple for a company that just grew revenue 33% year over year -- even accounting for the risks of a $125 billion-plus spending plan. That valuation multiple, of course, could come down if growth slows, but this multiple also hardly assumes another decade of dominance.

After all, the lesson of the decade-long backtest isn't that Meta was a once-in-a-generation bargain in 2016. It's that an enormously profitable business kept compounding while plenty of investors found reasons to sell along the way.

For long-term investors, I think Meta remains a solid holding today. I just wouldn't let a $58,000 backtest set my expectations for the next ten years.

FICO’s Big Dip Could Be the Best Buying Chance of the YearEquifax NYSE: EFX said it has signed a definitive agreement to acquire Círculo de Crédito, which Chief Executive Officer Mark Begor described as the fastest-growing credit bureau in Mexico, for an enterprise value of $750 million.

During an investor update call, Begor said the acquisition would expand Equifax into Mexico, “the second largest economy in Latin America,” and give Círculo de Crédito customers access to Equifax’s cloud-native technology, decisioning and analytics capabilities, EFX.AI technology, and identity protection and fraud prevention offerings.

Get Equifax alerts:

3 Stocks Just Announced Intentions to Buyback Near 10% of SharesThe transaction is expected to close in the fourth quarter, subject to customary closing conditions and regulatory approvals. Begor said Equifax has been focused on entering Mexico for years, including efforts during prior leadership, and that Círculo became the most attractive entry point after TransUnion acquired majority ownership in another Mexican bureau.

Financial Terms and Expected Impact Equifax said Círculo generated $134 million in revenue for the 12 months ended June 30, up 31%, with adjusted EBITDA margins of 46%. For full-year 2026, Círculo is expected to continue delivering high double-digit revenue growth with mid-40% adjusted EBITDA margins, according to Begor.

4 Undervalued Growth Stocks to Buy and Hold for the Long TermThe $750 million enterprise value represents an 11.7 times adjusted EBITDA multiple at closing based on Círculo’s expected 2026 adjusted EBITDA, Begor said. Including expected run-rate synergies, the multiple is expected to be about 9.4 times at closing.

Begor said the acquisition is expected to be accretive to Equifax adjusted earnings per share in the first full year of ownership and to deliver mid-double-digit returns, which he said would be “well above” Equifax’s cost of capital.

Equifax also said it expects to maintain balance sheet leverage below 3 times while completing the acquisition. Begor said the company expects free cash flow to exceed $1 billion in 2026 and has more than $1.5 billion in financial capacity. He said Equifax can complete the acquisition while continuing share repurchases, though at a slower pace than in the first half of 2026.

Mexico Market and Círculo’s Position Begor characterized Mexico as one of the fastest-growing credit markets globally, with consumer credit growth driven by expanded access to credit, financial inclusion and digitization. He said more than 25% of Mexico’s population lacks access to formal financial products and nearly 44% does not have a bank account.

Círculo is the only credit bureau in Mexico licensed to operate both consumer and commercial credit bureau services, according to Begor. He said the company has more than 1,700 customers across banks, retail, fintech, small business lending, microfinance and telecommunications, along with 2 billion trade lines covering 80 million validated identities.

Begor said Círculo’s growth has been supported by its position in alternative data, including gig economy transactions and utility payment history. He said more than 40% of Círculo’s 2025 revenue came from fintech customers, with that segment growing more than 50%.

Integration Plans and Synergies Equifax said it expects to generate synergies by deepening Círculo’s retail and fintech data position, expanding penetration with large financial institutions, and moving Círculo’s infrastructure onto Equifax’s cloud-native architecture.

Begor said Equifax plans to bring its global platforms and products into Mexico, including its Ignite analytics platform, InterConnect platform, scores, AI capabilities, fraud tools and identity products. He also said Equifax expects some Círculo products and fintech-related capabilities to be deployed in other markets.

The company pointed to its acquisition of Boa Vista in Brazil as a model for the Círculo integration. Begor said Boa Vista has outperformed Equifax’s expectations and gave the company confidence in its acquisition integration playbook.

Questions From Analysts In response to questions about Círculo’s recent growth, Begor said the company has benefited from the rapid expansion of fintechs, retailers and telecommunications providers in Mexico. He said many consumers without bank accounts may first build credit through retail financing, such as appliance or furniture purchases.

Asked about competition, Begor said TransUnion is currently in the Mexican market through its ownership of the previously bank-owned consumer credit bureau. He said Equifax believes Círculo is well positioned because of its data from retailers, fintechs and telecommunications providers.

Begor also addressed Mexico’s data-sharing structure. He said credit bureaus are required by law to share certain trade lines when a credit report is pulled, but positive data is unique to each bureau. He said Círculo’s positive data, more frequent reporting from some contributors and broad contributor base are important advantages.

On regulatory timing, Begor said Equifax believes its approval process could be faster than TransUnion’s recent acquisition process because Equifax has had an application with Mexican regulators for several years to form a credit bureau and has been engaged with them during that period.

Equifax said the Círculo transaction is part of its broader bolt-on acquisition strategy. Including Círculo, Begor said the company will have invested nearly $5 billion in 17 strategic bolt-on acquisitions since 2020, focused on differentiated data, workforce solutions, international markets, and identity and fraud capabilities.

About Equifax NYSE: EFXEquifax Inc NYSE: EFX is a global data, analytics and technology company that specializes in consumer and commercial credit reporting, decisioning tools and identity solutions. Headquartered in Atlanta, Georgia, Equifax is one of the three major consumer credit reporting agencies in the United States and provides credit information and related services to lenders, employers, governments and consumers worldwide.

The company's offerings include consumer credit reports and scores, credit monitoring and identity protection services, and a range of business-oriented products for risk management, fraud detection and compliance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Equifax Right Now?Before you consider Equifax, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Equifax wasn't on the list.

While Equifax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Microsoft Today

$385.10 +0.74 (+0.19%)

As of 07/10/2026 04:00 PM Eastern

52-Week Range$349.20▼

$555.45Dividend Yield0.95%

P/E Ratio22.92

Price Target$559.84

Microsoft Corp. NASDAQ: MSFT has taken steps to lessen its reliance on frontier AI models, though it's not an outright declaration of protest. In June, the tech giant launched its own proprietary AI models (Microsoft AI or MAI) across select applications in its Office suite.

What this means for the user experience is an open question, but this is a clear margin play for Microsoft. The company competes in multiple areas of the AI infrastructure buildout. In a way that makes this move about controlling the controllables.

Get Microsoft alerts:

Instead of experiencing death by a thousand cuts from OpenAI and Anthropic (i.e., the frontier models), Microsoft is trying to widen its existing moat and deliver strong returns on investment (ROI) from its AI spend. But will this be sufficient to alter the sentiment towards MSFT, which has declined approximately 20% year-to-date?

Microsoft Expands MAI to Reduce Reliance on OpenAIHere's the news behind the news. Bloomberg reported that Microsoft is quietly routing some Excel and Outlook prompts to MAI, its in-house model family, rather than to OpenAI or Anthropic. Tens of thousands of prompts a week are already running on Microsoft's own tech.

That's still a small slice of total Copilot traffic. OpenAI and Anthropic handle most of it today. But the direction of that travel matters more than the current split, and Microsoft has made its intentions clear.

At Build 2026 in June, Microsoft unveiled seven MAI models, including its first reasoning model, MAI-Thinking-1. The company says it matches Anthropic's Claude Opus 4.6 on coding tasks. AI chief Mustafa Suleyman put it bluntly: "We pay a lot of money to Anthropic, so our goal is to reduce and ultimately eliminate that cost."

How Microsoft's In-House AI Could Boost Profit MarginsFor investors, an easy way to think about this is as follows. Copilot is a $30-per-seat subscription that, prior to the MAI launch, was running on top of someone else's expensive AI model by default. Every prompt costs Microsoft money to process, and multiplied across hundreds of millions of Office users, that bill adds up fast.

Owning the model instead of renting it changes the equation entirely. Microsoft doesn't need MAI to win over every customer. It just needs MAI to be good enough for everyday spreadsheet formulas and email drafts, at a fraction of the cost.

That's the ROI story. Microsoft won’t win an AI arms race on raw intelligence. But it can compete more efficiently by converting a rented cost center into owned infrastructure.

Microsoft Uses MAI to Strengthen Its AI Competitive MoatMicrosoft chief executive officer (CEO) Satya Nadella has reportedly said he feared Microsoft becoming "the next IBM.” By that, he meant a company that let someone else own the most important layer of technology. MAI is Microsoft's answer to that fear.

Instead of a single point of AI dependency, Microsoft now runs a three-way hedge. It holds a stake in OpenAI, embeds Anthropic's Claude in Copilot, and increasingly leans on its own models where the economics make sense. That flexibility is arguably a bigger moat than any one model's benchmark score.

It also insulates Microsoft from a ticking clock. Microsoft's current discounted OpenAI pricing won't last forever, and that deal isn't set to expire until 2032. Building a credible in-house alternative now gives Microsoft leverage in any future renegotiation, rather than leaving it stuck paying whatever OpenAI or Anthropic decides to charge.

The Bear Case: Risks to Microsoft's AI StrategyBefore getting too bullish, a few caveats are worth weighing. This shift is still incremental, and Microsoft hasn't published any timeline for expanding it further. Most Copilot workloads still run on outside models today.

There's also a quality question. Microsoft's own materials frame MAI as matching prior-generation Anthropic models, not necessarily the current large language models (LLMs). If MAI-powered features feel noticeably worse, customer goodwill could take a hit that outweighs the cost savings.

What It Means for OpenAI and AnthropicThis is a warning shot worth watching. Anthropic filed confidentially for an IPO in June, and OpenAI is reportedly preparing a similar filing. Their biggest enterprise distribution partner is now also a competitor, building cheaper in-house alternatives.

That doesn't mean OpenAI or Anthropic are in immediate trouble. Both still handle the bulk of Copilot's AI traffic, and Microsoft has made it clear that it isn't ending either partnership. But the "picks and shovels" trade just got a little more complicated for anyone betting purely on third-party AI labs staying indispensable.

Microsoft Stock Rebounds After Hitting a 52-Week LowMicrosoft hit a 52-week low in late June. The 10% bounce off that level isn’t a sign that everything is perfect, but it does suggest that investors are leaning into the stock’s value proposition.

At around 22x forward earnings, Microsoft is trading at a discount to the S&P 500 and to its own history. An argument could be made that MSFT wasn’t overvalued when the sell-off began in November, and there’s ample reason to believe it’s undervalued now. The relative strength indicator reached oversold territory when MSFT bottomed in June.

But a larger story comes from analysts and institutions. The MSFT consensus price target of $559.84 is approximately 45% below its recent trading range. Plus, out of 48 analysts tracked by MarketBeat, 41 give MSFT a Buy rating, and seven rate it as a Hold. Analysts notoriously don’t like to be wrong, which may explain why some analysts have trimmed their price targets, but the overall sentiment remains bullish.

The same cautious optimism can be found in its institutional ownership. There's no question that buying has slowed in the first two quarters of the year. But buying still outpaces selling, and with MSFT at 22x earnings, this could be an attractive target for money that hasn’t left the market and is looking for growth in the second half.

Should You Invest $1,000 in Microsoft Right Now?Before you consider Microsoft, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microsoft wasn't on the list.

While Microsoft currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners

, /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer's Association International Conference® (AAIC®) 2026 in London support that the LEQEMBI® (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration for people with early Alzheimer's disease (AD). The data was featured during the "Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations" Developing Topics Session #1-32-FRS-C.

AD is a chronic, progressive disease that requires ongoing treatment. LEQEMBI is an early AD treatment that targets the underlying pathology of the disease, helping to slow cognitive decline and loss of daily functioning. The lecanemab subcutaneous auto‑injector (SC‑AI) was developed to provide a more convenient alternative to intravenous (IV) dosing from the initiation of treatment.

Key Findings
This session presented data from the lecanemab SC-AI development program in early Alzheimer's disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience findings. Results showed that once-weekly 500 mg SC-AI achieved drug exposure similar to the approved intravenous (IV) initiation regimen (10 mg/kg every two weeks), supporting the expectation of similar clinical efficacy and safety, independent of the route of administration.

If approved by the United States Food and Drug Administration (FDA), subcutaneous dosing for initiation may offer a convenient at-home alternative to IV infusion which could support access and delivery of care across healthcare settings.

Data Showed

Bioequivalence Achieved: Once-weekly 500 mg SC-AI demonstrated bioequivalence to the IV initiation regimen (10 mg/kg every two weeks), with an exposure ratio of 104% (90% confidence interval [CI]: 99.1%–109%). Exposure remained consistent across body weight quartiles, demonstrating a stable pharmacokinetic profile in a broad patient population. Efficacy Driven by Exposure, Not Route of Administration: Amyloid removal measured by amyloid PET, clinical efficacy measured by CDR-SB, and the incidence of ARIA-E were driven by lecanemab exposure rather than route of administration. The 500 mg SC-AI initiation regimen achieved exposure comparable to the IV initiation regimen, supporting the expectation of a comparable efficacy and safety profile despite the different route of administration. Consistent Results Across Patient Populations: The 500 mg SC-AI initiation regimen demonstrated consistent exposure, amyloid clearance as measured by amyloid PET, clinical efficacy and safety across body weight groups. In addition, amyloid clearance and clinical outcomes were not meaningfully affected by body weight, supporting the appropriateness of a fixed-dose regimen. Flexible switching between IV and SC administration: Patients may also switch from IV to SC administration, or vice versa, and if a dose is missed patients can take it the next day or up to day six providing greater convenience and flexibility in LEQEMBI administration. Safety Profile Aligned of SC LEQEMBI

Overall safety profile of SC-AI was generally consistent with that observed for the IV formulation. Incidence of ARIA-E with the 500 mg SC-AI initiation regimen was predicted to be similar to that observed with the IV initiation regimen. Injection-related reactions were observed with subcutaneous LEQEMBI, most of which were localized, while systemic reactions were less frequently observed. The incidence of anti-drug antibodies (ADA) was low, at 1.4% in the 500 mg SC-AI group. No neutralizing antibodies were observed, confirming that the low immunogenicity profile was maintained with the SC-AI formulation. Clinical Trial Perspectives and Real-World Evidence: Sustained Clinical Benefit with SC-AI

Data from two U.S. Alzheimer's treatment centers (Alzheimer's Research and Treatment Center, and First Choice Neurology and Visionary Investigators Network) provide early insight into clinical trial and real-world use of subcutaneous LEQEMBI: At Alzheimer's Research and Treatment Center, 28 patients receiving SC administration demonstrated slower cognitive decline as measured by CDR-SB over 36 months relative to a matched Alzheimer's Disease Neuroimaging Initiative (ADNI) natural history cohort. The cohort included 25 patients newly initiated on SC administration and 3 patients who transitioned from IV administration.  In a separate case series from First Choice Neurology and Visionary Investigators Network, 10 of 11 evaluable patients (91%) showed improvement or remained stable on MMSE compared with baseline before maintenance therapy. At this center, patients who had received maintenance therapy with SC administration for at least 6 months were included in the analysis. Patient and care partner surveys in these two sites demonstrated high satisfaction with subcutaneous LEQEMBI administration, with satisfaction rates ranging from 75% to 97%, convenience ratings from 83% to 97%, and willingness to recommend treatment ranging from 92% to 100%. Results presented in this session further reinforce the importance of early and continuous treatment, highlighting how LEQEMBI SC initiation and maintenance administration provides greater optionality for long-term disease management.

Eisai serves as the lead for lecanemab's development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.

MEDIA CONTACTS

Eisai Co., Ltd.

Public Relations Department

TEL: +81 (0)3-3817-5120

Eisai Europe, Ltd.  

EMEA Communications Department 

+44 (0) 797 487 9419 

[email protected] 

Eisai Inc. (U.S.)

Libby Holman

+1201-753-1945

[email protected] 

Biogen Inc.

Madeleine Shin

+1-781-464-3260

[email protected]

INVESTOR CONTACTS

Eisai Co., Ltd.

Investor Relations Department

TEL: +81 (0) 3-3817-5122

Biogen Inc.

Tim Power

+ 1-781-464-2442

[email protected]

Notes to Editors

About lecanemab (generic name, brand name: LEQEMBI®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China.

Since July 2020, the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai, and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

About Protofibrils
Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.1 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.2

About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.

About Eisai Co., Ltd.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for lecanemab-irmb (LEQEMBI IQLIK); the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including  lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q, Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References

Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021; 12:3451. doi: 10.1038/s41467-021-23507-z. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. SOURCE Eisai Inc.

Shares of Gilead Sciences (GILD 3.72%) have lagged the S&P 500 average this year, rising only 9% despite strong financials and a pipeline that promises to elevate the pharmaceutical company's base beyond its core of HIV therapies.

Gilead has spent heavily on its acquisitions of Arcellx, Ouro Medicines, and Tubulis, and while it will take time to integrate them, the upside is that they add to the company's pipeline, particularly in oncology and inflammation therapies.

In its first-quarter presentation, the company said it has four potential launches this year. Instead of focusing on the cost of its purchases, investors would do well to look beyond that and see how these new launches and acquisitions will diversify Gilead's platform, reducing its reliance on its HIV franchise.

Three reasons to buy Gilead right now:

Image source: Getty Images.

The company's continued financial strength In Q1, Gilead reported revenue of $7 billion, up 4% year over year, mainly from higher sales of its HIV products. Earnings per share (EPS) were $1.61, up 54.8% over the same period last year. It's not as if the company's HIV therapies are slowing down. Biktarvy and Descovy continue to dominate market share, driving a 10% year-over-year increase in HIV product sales to $5 billion.

The company is also seeing significant growth in its breast cancer drug, Trodelvy, with sales up 37% year over year. This dependable revenue gives it product gross margins of roughly 79%. The company said it sees no major loss-of-exclusivity patent cliffs for its top drugs until 2036. This means at least another decade of secure cash flows to fund research and development and dividend growth.

Today's Change

(

-3.72

%) $

-5.01

Current Price

$

129.83

High-impact 2026 commercial launches The primary reason to look at Gilead right now is its massive, immediate product-launch calendar.

Bulevirtide was given accelerated approval on May 22 by the Food and Drug Administration (FDA) as the first treatment for adults with chronic hepatitis delta virus (HDV) infection who do not have cirrhosis (severe liver scarring) or who have compensated cirrhosis. The FDA on April 29 granted Priority Review for a once-daily, single-tablet combo regimen of bictegravir + lenacapavir (BIC/LEN) for adults with suppressed HIV, with a critical Prescription Drug User Fee Act (PDUFA) action date set for Aug. 27, and launch expected shortly thereafter.

With its purchase of Arcellx, the company gains multiple myeloma therapy anito-cel, a BCMA CAR-T therapy with a PDUFA date scheduled for December. Trodelvy also continues to gain ground, with FDA approval on June 24 that allows it to move into crucial first-line metastatic triple-negative breast cancer (mTNBC) indication.

In addition, Gilead's twice-yearly injectable HIV prevention drug, Yeztugo, has entered its multimarket launch curve following a strong clinical performance, and the company said it expects $1 billion in 2026 sales from the drug.

The price is right, and so is its dividend Despite a strong five-year run and solid operational execution, Gilead's valuation remains highly attractive, trading at around 15 times forward earnings, well below its five-year average.

For income-oriented investors, Gilead pairs this growth inflection with a reliable 2.39% dividend yield at its current share price. The company has increased its dividend for 11 consecutive years, including a 3.7% bump this year.

U.S. airstrikes on Iran kept markets on edge last week, even as stocks near record highs mostly held their ground. For anyone wondering how the market's most disciplined capital allocator is set up for a moment like this, Berkshire Hathaway (BRKB 0.35%)(BRKA +0.00%) offers a clear answer.

It is holding more cash than at any point in its history.

Famous investor Warren Buffett handed the chief executive job to Greg Abel at the end of 2025 and stayed on as chairman. But the cautious posture he spent years building hasn't changed. At the end of the first quarter, Berkshire's cash and short-term Treasury bills reached a record of about $397 billion.

This raises the question: What does a hoard this size from a disciplined conglomerate with a storied history of making good investments say about where prices stand today?

Warren Buffett. Image source: The Motley Fool.

A record pile, and a steady seller Berkshire's balance sheet at the end of March held about $58.1 billion in cash and equivalents, plus roughly $339 billion in short-term U.S. Treasury bills. Together, that is close to $397 billion sitting in the safest assets around, equal to more than a third of the entire company's market value. By Berkshire's own measure, cash has never stood so high as a share of the company.

And Berkshire keeps adding to it. In the first quarter, the company sold about $24 billion of stocks while buying only about $16 billion. That extends a net-selling streak that now runs more than three years.

The cash is hardly idle, either. At recent Treasury yields near 3.7%, the pile earns something like $12 billion a year in interest, more than many companies in the S&P 500 report in annual profit.

This isn't necessarily a market call. Buffett has long framed cash as optionality, the ability to move decisively when something cheap comes along, and Berkshire simply hasn't found enough it wants to buy at today's prices. After all, the company has to put tens of billions to work to move its own needle, so it can afford to wait for a pitch that smaller investors might swing at sooner.

Still, when the most famous value investor of the past century would rather collect a risk-free 3.7% than buy more of what's on offer, that itself says something. Personally, I take it as a quiet comment on valuations.

Today's Change

(

-0.35

%) $

-1.74

Current Price

$

493.71

What the cash has signaled before This isn't the first time Berkshire has let cash pile up. In the late 1990s, as technology stocks soared, Buffett sat out the mania and took plenty of criticism for it, until the dot-com bust vindicated the patience.

Cash climbed again ahead of the 2008 financial crisis. And when prices finally cracked, Berkshire deployed aggressively, most famously with a $5 billion investment in Goldman Sachs in September 2008 that paid a 10% dividend, on terms an ordinary investor could never get.

The pattern is fairly consistent. Berkshire tends to accumulate cash when it finds few bargains, then spend it when fear creates them.

Of course, that doesn't mean a crash is coming. Buffett himself has warned against treating his cash position as a market forecast, and Berkshire has held plenty of cash through stretches when stocks just kept climbing.

What's new this time, however, is who decides when the money gets spent. Abel, not Buffett, now largely controls when this war chest gets put to work. How he deploys it may be the single biggest factor in Berkshire's returns over the next several years, and so far he has stuck to the same disciplined script. Yes, he's bought some Alphabet stock and even agreed to acquire Taylor Morrison Home. But as of the end of Q1, Berkshire remained a net seller of stocks.

So what does all of this tell investors? Not that a crash is around the corner. Buffett would likely be the first to reject that conclusion. What it does say is that patience is reasonable when prices are this high, and that Berkshire has quietly positioned itself to act if the mood sours.

Redwire (RDW 2.77%), a producer of space mission components, went public through a merger with a special purpose acquisition company (SPAC) on Sept. 3, 2021. Its stock opened at $11.07, set a record high of $25.90 on May 28, 2026, but now trades at $10.18 per share.

Redwire initially impressed investors with its robust revenue growth, but some concerns about its dilution, widening losses, and accounting accuracy crushed its stock. Does that 61% pullback from its all-time high represent a buying opportunity or a bright red flag?

Image source: Getty Images.

How fast is Redwire growing? Redwire develops critical navigation, power, and 3D-printing components for satellites, space stations, and other spacecraft. It also builds military drones and custom components for missile defense and military communications systems. Its customers include NASA, the Department of Defense, and large commercial space contractors.

Today's Change

(

-2.77

%) $

-0.29

Current Price

$

10.18

In 2025, Redwire's revenue rose 10% to $335 million, but its net loss nearly doubled from $114 million to $227 million. Those widening losses were caused by higher estimated project completion costs, goodwill impairment charges from its recent acquisitions, increased spending on its military drone projects, and higher stock-based compensation expenses.

From 2025 to 2028, analysts expect Redwire's revenue to grow at a 26% CAGR to $664 million as it narrows its net loss to $43 million. That growth should be driven by the construction of orbital data centers, more low Earth orbit (LEO) satellites, new lunar missions, and the development of more sophisticated drones for the U.S. military.

What problems does Redwire face? Redwire ended the first quarter of 2026 with $175 million in total liquidity. But on June 9, it announced an at-the-market (ATM) equity offering to sell up to $500 million in new common stock. That's a lot of dilution compared to its market cap of $2.4 billion. It's already increased its share count by 232% since its public debut.

To make matters worse, Redwire received an "adverse internal controls opinion" from its auditor, KPMG, after its 2025 report. That opinion is a bright red flag, since it suggests Redwire's internal financial controls are unstable and could increase its risk of serious accounting errors.

Those headwinds, along with its persistent losses and a waning interest in space stocks after SpaceX's record-setting IPO cooled off, sent Redwire's stock crashing. It might seem reasonably valued at five times this year's sales, but its dilution and potential accounting issues make it an unattractive investment. I'd rather stick with some of the market's more resilient space stocks than this speculative supply chain player.